# Patient Care Plan

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Thomas Jefferson (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-EN005-SYN
- Date: 2026-05-07
- Fictional facility: St. Posthumous Health Center
- Fictional author: Nathaniel Beaumont-Ruiz, MD
- Calendar frame: modern shifted

## What we are working on

- Headaches in bouts that come on in the morning and stop him reading or writing for days or weeks, now at the start of a demanding new post **S**
- He wants to know whether something serious is causing them, and whether anything works better than the remedies he has tried **S**
- Writing by hand is slow and painful because of an old wrist injury, and his work depends on writing **S**

## Your goals

- A two-week headache diary that allows a firm diagnosis. Target: 2026-05-21. Recorded outcome: Diary of 14 days kept; ICHD-3 criteria for migraine without aura met; no red flags. **S**
- Monthly migraine days reduced by at least half within three months of starting prevention. Target: 2026-08-13. Recorded outcome: From 13 migraine days in the four weeks before prevention to 3 in the last four weeks. **S**
- Acute medicine on no more than two days a week, so that medication overuse headache does not develop. Target: 2026-08-13. Recorded outcome: Acute medicine on 3 days in the last four weeks; no combination analgesic or caffeine pill since intake. **S**
- Pain-free within two hours of acute treatment in most attacks. Target: 2026-08-13. Recorded outcome: Pain-free at two hours in 6 of 8 attacks treated with sumatriptan and naproxen since the consultation. **S**
- Lower headache-related disability. Target: 2026-08-13. Recorded outcome: MIDAS 39 (grade IV) to 13 (grade III); the three-month recall still includes the end of the May bout. **S**
- Write for longer without wrist pain. Target: 2026-08-13. Recorded outcome: Dictation and a wrist splint for long writing; about two hours with breaks. **S**

## What we agreed to do

- Diagnosis: a structured headache history, a red-flag screen (SNNOOP10) at every visit, a 14-day headache diary of attacks, features, triggers and medicine days, and ICHD-3 criteria; no neuroimaging for a stable long-standing pattern without red flags, with clear reasons that would change that. Guideline: Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3rd edition (2018); The American Headache Society Consensus Statement: Update on integrating new migraine treatments into clinical practice (2021); Choosing wisely in headache medicine: the American Headache Society's list of five things physicians and patients should question (2013) **S**
- Neurology (headache medicine) consultation to confirm the diagnosis and advise on acute and preventive treatment. Guideline: The American Headache Society Consensus Statement: Update on integrating new migraine treatments into clinical practice (2021); Calcitonin gene-related peptide-targeting therapies are a first-line option for the prevention of migraine: An American Headache Society position statement update (2024) **S**
- Acute treatment at intake: naproxen early in an attack, with metoclopramide for nausea, no more than two days a week; stop the over-the-counter combination analgesic with caffeine; no opioids or butalbital. Guideline: The American Headache Society Position Statement On Integrating New Migraine Treatments Into Clinical Practice (2019); Pharmacologic Treatments of Acute Episodic Migraine Headache in Outpatient Settings: A Clinical Guideline From the American College of Physicians (2025); Choosing wisely in headache medicine: the American Headache Society's list of five things physicians and patients should question (2013) **S**
- Acute treatment after the diagnosis: sumatriptan 100 mg with naproxen early in a migraine attack, a second sumatriptan dose after two hours if needed; a gepant or lasmiditan if a triptan fails or becomes unsuitable. Guideline: The American Headache Society Consensus Statement: Update on integrating new migraine treatments into clinical practice (2021); The American Headache Society Position Statement On Integrating New Migraine Treatments Into Clinical Practice (2019); Pharmacologic Treatments of Acute Episodic Migraine Headache in Outpatient Settings: A Clinical Guideline From the American College of Physicians (2025) **S**
- Medication overuse headache prevention: acute-medicine days counted in the diary, with limits of fewer than 10 days a month for a triptan or combination analgesic and fewer than 15 for an NSAID; never caffeine pills or combination products. Guideline: Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3rd edition (2018); The American Headache Society Consensus Statement: Update on integrating new migraine treatments into clinical practice (2021) **S**
- Preventive treatment, since bouts bring six or more migraine days a month with severe disability: propranolol extended-release, starting at 80 mg and raised to 120 mg if tolerated, with pulse, blood pressure, energy and mood checked; efficacy judged at two to three months (at least half as many migraine days); a CGRP monoclonal antibody as the next option, or sooner if propranolol is not tolerated; topiramate and amitriptyline not chosen because of their effects on concentration and morning alertness. Guideline: The American Headache Society Consensus Statement: Update on integrating new migraine treatments into clinical practice (2021); Calcitonin gene-related peptide-targeting therapies are a first-line option for the prevention of migraine: An American Headache Society position statement update (2024); Prevention of Episodic Migraine Headache Using Pharmacologic Treatments in Outpatient Settings: A Clinical Guideline From the American College of Physicians (2025); Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults (2012) **S**
- Lifestyle and triggers: a fixed wake and sleep time, regular meals on working days, a steady modest amount of caffeine, fluids, daily walks, and a stress plan for long working days with breaks from reading; relaxation training and biofeedback offered. Guideline: The American Headache Society Consensus Statement: Update on integrating new migraine treatments into clinical practice (2021) **S**
- Wrist and writing: an occupational therapy visit for hand function, a wrist splint for long writing sessions, dictation software, and a desk set up to spare the wrist and neck. Guideline: The American Headache Society Consensus Statement: Update on integrating new migraine treatments into clinical practice (2021) **S**

## Follow-up

- 2026-05-07: Establishing primary care for recurrent disabling headaches, seven days into a bout: headache history and red-flag screen, a headache diary, disability and mood screening, acute treatment, avoiding medication overuse, and an old right wrist injury that slows his writing **S**
- 2026-05-21: Two-week review of the headache diary, seen the same day by headache medicine: diagnosis, acute treatment and the decision on preventive treatment **S**
- 2026-06-18: Six-week review, four weeks after starting propranolol: tolerability, attacks, acute medicine days and the wrist **S**
- 2026-07-16: Periodic adult preventive visit **S**
- 2026-08-13: Three-month review: response to prevention, disability, acute medicine use and the plan ahead **S**

This teaching document does not replace care from a qualified clinician.
